数据链接：
官方服务：
资源简介：
Progression rate of observation and treatment group.
应用场景：
创建时间：
2021-07-15
相关数据集
Randomized phase 2 study of mFOLFOX6 plus bevacizumab versus modified OPTIMOX plus bevacizumab for metastatic colorectal cancer
Interventions: After 8 cycles of mFOLFOX 6 plus bevacizumab, patients receive UFT/LV with bevacizumab (until 5 cycles are completed or disease progression). And then, patients receive modified FOLFOX6
NIAID Data Ecosystem70
Baseline characteristics of patients enrolled in the effective and placebo/ineffective treatment groups.
Median and interquartile range or percentages are shown. EULAR responder = good or moderate responder according to the European League Against Rheumatism Response, TJC68 = tender joint count of 68 jo
NIAID Data Ecosystem50
Dataset from Study of Once-Daily Versus Twice-Daily Fosamprenavir Plus Ritonavir, Administered With Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects.
This is a Phase IIIB, 48 Week, multicentre, randomized, open-label, parallel group study comparing the safety and efficacy of fosamprenavir plus ritonavir 1400mg/100mg once-daily to fosamprenavir pl
NIAID Data Ecosystem30
Comparisons between study arms after 2 months of treatment.
*PBMC (1×106) stimulated by PMA (50 ng/ml) and inomycin (1 µg/ml) for 16 hours.**95% confidence intervals (CI) are for mean differences between the two groups.
Figshare2015-12-02 更新60
A Study of Ramucirumab or Icrucumab in Colorectal Cancer
The purpose of this study is to determine if participants with metastatic colorectal cancer live longer without their cancer progressing when treated with standard chemotherapy, standard chemotherapy
NIAID Data Ecosystem40
